= 7). Virologic failure occurred in 4 patients (2%) and was often accompanied by emergent or pre-existing non-nucleoside reverse transcriptase inhibitor and/or integrase strand transfer inhibitor resistance mutations; all patients achieved resuppression after switching back to oral ART. LA CAB/RPV was generally well tolerated, but system-level access and care-continuity barriers were major drivers of discontinuation, underscoring the importance of robust support systems and resistance-informed patient selection.
Hockney et al. (Tue,) studied this question.